Syros is redefining the power of small molecules to control gene expression with the aim of providing a profound benefit for patients. We are advancing a pipeline of gene control medicines for hematologic malignancies.

Latest Annual Report

For Year Ending December 31, 2022

View Annual Report

Stock Information

Syros Pharmaceuticals, Inc.


Nasdaq: SYRS




52 week Low/High

Day Low/High

Company Overview

Syros is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is focused on advancing a late-stage clinical pipeline, including tamibarotene, an oral selective RARĪ± agonist in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression, and SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia. Syros is seeking out-licensing opportunities for SY-5609, a highly selective and potent CDK7 inhibitor in clinical development for the treatment of select solid tumors, and for multiple preclinical programs in oncology.

Latest Presentation


Our people are our backbone. Touting years of experience in a variety of fields, our leadership team is the source of our success.

IR Contact Information

Investor Relations

Syros Pharmaceuticals
Karen Hunady
Director of Corporate Communications & Investor Relations

Stern Investor Relations, Inc.
Hannah Deresiewicz

Transfer Agent

Computershare Trust Company, N.A.